ADAM metallopeptidase with thrombospondin type 1 motif 20Genealiases: ADAM-TS20 · ADAMTS-20 · GON-1
Q-omics provides the consensus-scored ADAMTS20 profile across patient tissues and cancer cell-line models. ADAMTS20 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in SCLC. Among the 18 cancer types available for tumor–normal comparison, ADAMTS20 is differentially expressed in 8, with the highest sampling consensus in HNSC. Additionally, ADAMTS20 RNA expression shows 15,147 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight SCLC, HNSC, and THYM as cancer lineages where ADAMTS20 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ADAMTS20 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ADAMTS20 survival associations across molecular data types. ADAMTS20 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (8). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ADAMTS20 RNA expression–survival associations across cancer types. High ADAMTS20 expression shows unfavorable associations in UVM, ACC and LIHC, but favorable associations in SCLC, LGG and LUSC. The SCLC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify SCLC as the clearest survival context for ADAMTS20 RNA expression.
This table summarizes ADAMTS20 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for ADAMTS20. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ADAMTS20 shows higher tumor expression in HNSC, KIRC, LUSC, BLCA, BRCA and LUAD. The HNSC box plot shows higher ADAMTS20 RNA expression in tumor versus normal tissue (log2 FC = +0.557, t-test p < 0.001).
This table shows molecular features associated with ADAMTS20 in patient tissues and cancer cell lines. In patient samples, ADAMTS20 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, ADAMTS20 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in URINARY_TRACT, while CRISPR and shRNA rows add functional-dependency signals in STOMACH and LARGE_INTESTINE.
